Stevanato Group SPA (Stevanato Group SPA) Interest Expense : $-5 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Stevanato Group SPA's interest expense for the three months ended in Mar. 2024 was $ -2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Stevanato Group SPA's Operating Income for the three months ended in Mar. 2024 was $ 27 Mil. Stevanato Group SPA's Interest Expense for the three months ended in Mar. 2024 was $ -2 Mil. Stevanato Group SPA's Interest Coverage for the quarter that ended in Mar. 2024 was 16.50. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Stevanato Group SPA Interest Expense Historical Data

The historical data trend for Stevanato Group SPA's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA Interest Expense Chart

Stevanato Group SPA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-6.23

-7.29

-5.50

-4.17

-4.71

Stevanato Group SPA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial													-1.07	-0.71	-1.22	-1.67	-1.67

Stevanato Group SPA Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5 Mil.

Stevanato Group SPA (NYSE:STVN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Stevanato Group SPA's Interest Expense for the three months ended in Mar. 2024 was $-2 Mil. Its Operating Income for the three months ended in Mar. 2024 was $27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $305 Mil.

Stevanato Group SPA's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	27.489	/	-1.666
	=	16.50

The higher the ratio, the stronger the company's financial strength is.

Stevanato Group SPA (Stevanato Group SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

87N:Germany

Address

Via Molinella 17, Piombino Dese, Padua, ITA, 35017

Website

https://www.stevanatogroup.com

Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.